EDAP TMS S.A. (EDAP) स्टॉक विश्लेषण

कंपनी का अवलोकन

EDAP TMS S.A. is a specialized entity engaged in the development, manufacturing, promotion, and distribution of minimally-invasive medical devices designed for urology applications that rely on proprietary ultrasound technology. The company operates within the Healthcare sector and specifically functions in the Medical Distribution industry, serving markets across Asia, France, the United States, and internationally. In terms of scale, the entity possesses a market capitalization of $125.94M while generating total annual revenue of $70.53M for the trailing twelve months. The available employee count is listed as N/A, which suggests that the company's operational scale is driven primarily by its technological assets and distribution network rather than a massive workforce. The combination of a market cap near $126M and revenue slightly above $70M indicates that the company is a mid-cap player within the niche medical device sector, likely focusing on high-margin proprietary technologies rather than broad-scale manufacturing.

वित्तीय स्वास्थ्य

The financial performance for the trailing twelve months shows a revenue of $70.53M, yet this is offset by a net income of $-29,246,000 and an EBITDA of $-21,288,000. The significant negative gap between the $70.53M revenue and the substantial net loss reveals a cost structure where operating expenses and taxes heavily outweigh gross profits, resulting in an inability to convert sales into retained earnings. The company generated free cash flow of $-12,130,500, which indicates a lack of financial flexibility as current operations are consuming cash reserves rather than generating surplus liquidity for reinvestment or debt repayment. Profitability is further eroded by a profit margin of -41.5%, an operating margin of -26.2%, and a gross margin of 42.5%, showing that while the core product sales maintain a healthy markup, downstream costs are destroying overall profitability. On the balance sheet, the company holds $20.45M in cash against $27.75M in debt, resulting in a debt-to-equity ratio of 142.93, which signifies a highly leveraged position where liabilities significantly exceed equity. Despite the high leverage, the current ratio stands at 1.54, indicating that the company maintains sufficient short-term liquid assets to cover its immediate obligations without immediate distress. Furthermore, the return on equity is -94.5% and the return on assets is -18.3%, metrics that reveal that management is currently ineffective at generating value for shareholders or utilizing the asset base to produce positive returns.

मूल्यांकन आकलन

Valuation metrics present a complex picture given the company's losses, with a trailing P/E ratio of N/A and a forward P/E of -5.79. The forward P/E being negative while the trailing P/E is unavailable implies that the market expects earnings to remain negative or volatile in the near term rather than anticipating an immediate recovery to profitability. The price-to-book ratio is 6.49, which indicates that the market is pricing the company at a significant premium over its net book value, suggesting high expectations for future asset appreciation or intangible value despite current losses. Alternative valuation measures include a price-to-sales ratio of 1.79 and an EV/EBITDA of -6.26, which suggest that investors are valuing the firm based on its revenue generation potential and market size rather than current earnings power. The stock has traded between a 52-week high of $5.05 and a 52-week low of $1.21, with the current trading price situated within this range reflecting recent market sentiment shifts. The beta value is -0.08, a highly unusual figure that suggests the stock price moves inversely to the broader market or exhibits negligible correlation with general market volatility, making its price behavior distinct from standard healthcare sector peers.

Growth & Income

Revenue growth for the year-over-year period is -19.0%, while earnings growth is N/A due to the lack of positive earnings data. The decline in revenue combined with the absence of earnings growth indicates that the company is contracting in the market and failing to expand its profit base simultaneously. The company does not pay a dividend, evidenced by a dividend yield of N/A and a payout ratio of 0.0%. Consequently, the company reinvests its limited resources or retains cash to sustain operations rather than distributing income to shareholders. The overall growth and income profile is characterized by revenue contraction and a complete absence of dividend income, highlighting a business model currently focused on survival and potential turnaround efforts rather than shareholder returns. The negative beta of -0.08 further complicates the investment thesis by decoupling the stock's performance from standard growth or income metrics found in the broader healthcare market.